You are here: Industry Insights > cardiovascular

News List

ACC: Long-Term Outcomes for MI Similar at ≤40, 40 to 50 drugs
March 08, 2019
Patients with myocardial infarction (MI) at age 40 years or younger have similar long-term all-cause and cardiovascular death rates as patients aged older than 40 years, according to a study presented at the annual meeting of the American College of Cardi
Blackstone, Novartis found cardiovascular startup with $250M fiercebiotech
February 28, 2019
Blackstone Life Sciences has committed $250 million to create a cardiovascular startup with Novartis. The biotech, Anthos Therapeutics....
Vivacelle Bio Receives FDA Clearance to Enroll Patients into its Phase IIa Trial of VBI-1 americanpharmaceuticalreview
February 18, 2019
Vivacelle Bio announced the US. Food and Drug Administration (FDA) has granted it an Investigational New Drug (IND) clearance to proceed with its phase IIa clinical trial of the safety and ....
Frequent use of aspirin can lead to increased bleeding worldpharmanews
January 23, 2019
A new study published today in the Journal of the American Medical Association (JAMA) has found that taking aspirin on a regular basis to prevent heart attacks and strokes, can lead to an increase risk of almost 50% in major bleeding episodes.
Luye Pharma strengthens commitment to cardiovascular therapeutic field biospectrumasia
January 17, 2019
Luye Pharma grants AstraZeneca exclusives rights to promote Xuezhikang Capsules in mainland China.
Sleeping less than six hours a night may increase cardiovascular risk worldpharmanews
January 17, 2019
People who sleep less than six hours a night may be at increased risk of cardiovascular disease compared with those who sleep between seven and eight hours, suggests a new study published in the Journal of the American College of Cardiology.
Increasing dose of statins could save more lives europeanpharmaceuticalreview
December 10, 2018
A study has shown that thousands of heart attacks and deaths caused by cardiovascular disease could be prevented through the use of statins…
Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis biospectrumasia
October 24, 2018
Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Eisai announces long-term cardiovascular outcomes data for anti-obesity Agent biospectrumasia
August 29, 2018
CAMELLIA-TIMI 61, conducted in collaboration with the Thrombolysis in Myocardial Infarction (TIMI) Study Group of Brigham and Women's Hospital, was a 12,000 patient study of BELVIQ at over 400 sites in eight countries.
Carmelina Cardiovascular Outcome Trial met its Primary Endpoint americanpharmaceuticalreview
July 24, 2018
Carmelina met its primary endpoint, defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3-point MACE), with Trajenta (linagliptin) demonstrating similar cardiovascular safety compared to placeb

Previous page 1 2 3 4 5 6 7 8 9 10 Next page